The Effect of Esmolol on Tissue Perfusion and Clinical Prognosis of Patients with Severe Sepsis: A Prospective Cohort Study

Table 2

Chi-square test and -test of the baseline characteristics of the patients (mean).

Base value	Esmolol group ()	Control group ()
Male, (%)	54 (72.0)	53 (69.7)	0.094	0.760
APACHE-II score, mean ± standard deviation	24.20 ± 7.66	25.46 ± 7.83	−0.999	0.319
HR, mean ± standard deviation	125.04 ± 13.28	127.21 ± 13.88	−0.982	0.328
MAP, mean ± standard deviation	74.71 ± 7.28	75.89 ± 6.61	−1.051	0.295
CVP, mean ± standard deviation	12.45 ± 3.16	11.99 ± 3.35	0.881	0.380
IS, mean ± standard deviation	10.99 ± 2.08	11.11 ± 1.81	−0.374	0.709
Lac, mean ± standard deviation	8.98 ± 3.09	9.74 ± 4.05	−1.301	0.195
P(va)CO2, mean ± standard deviation	9.54 ± 3.89	10.12 ± 3.52	−0.947	0.345
ScvO2, mean ± standard deviation	0.77 ± 0.06	0.78 ± 0.06	−0.537	0.592

Note: APACHE-II: Acute Physiology and Chronic Health Evaluation II; HR: heart rate; MAP: mean arterial pressure; CVP: central venous pressure; IS: vasoactive-inotropic score; Lac: arterial blood lactate; P(va)CO₂: venous-arterial carbon dioxide partial pressure; ScvO₂: central venous oxygen saturation.